151. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.
- Author
-
David B Hanna, Kate Buchacz, Kelly A Gebo, Nancy A Hessol, Michael A Horberg, Lisa P Jacobson, Gregory D Kirk, Mari M Kitahata, P Todd Korthuis, Richard D Moore, Sonia Napravnik, Pragna Patel, Michael J Silverberg, Timothy R Sterling, James H Willig, Ann Collier, Hasina Samji, Jennifer E Thorne, Keri N Althoff, Jeffrey N Martin, Benigno Rodriguez, Elizabeth A Stuart, Stephen J Gange, and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA)
- Subjects
Medicine ,Science - Abstract
BACKGROUND:U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes. METHODS:We analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a first reported CD4+
- Published
- 2013
- Full Text
- View/download PDF